Enlivex Therapeutics Secures $212M in Private Placement Financing to Advance Longevity Drug Programs

Enlivex Therapeutics has closed a $212 million private placement, one of the largest single financing events for a longevity-focused company in recent memory. The deal signals growing institutional appetite for companies working at the intersection of aging biology and therapeutic development. The financing was completed at a premium to market price, and the capital will fund clinical program advancement, including trial enrollment and data generation for Enlivex's pipeline candidates. The company's Allocetra platform focuses on macrophage reprogramming, a therapeutic approach that aims to modulate the immune system by retraining immune cells to resolve inflammation rather than perpetuate it.